10.01
2.86%
-0.32
前日終値:
$10.33
開ける:
$10.05
24時間の取引高:
81,208
Relative Volume:
0.47
時価総額:
$1.16B
収益:
$7.50M
当期純損益:
$-81.89M
株価収益率:
0.358
EPS:
27.9585
ネットキャッシュフロー:
$-63.58M
1週間 パフォーマンス:
-11.35%
1か月 パフォーマンス:
+3.99%
6か月 パフォーマンス:
+26.86%
1年 パフォーマンス:
+314.67%
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
MESO | 10.02 | 1.16B | 7.50M | -81.89M | -63.58M | 27.96 |
VRTX | 447.70 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.97 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 590.57 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.15 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.89 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-09-24 | アップグレード | Maxim Group | Hold → Buy |
2024-08-29 | アップグレード | Jefferies | Hold → Buy |
2024-07-23 | アップグレード | Piper Sandler | Neutral → Overweight |
2023-08-31 | アップグレード | Jefferies | Hold → Buy |
2023-08-07 | ダウングレード | Maxim Group | Buy → Hold |
2023-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
2023-08-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
2023-03-09 | 開始されました | William Blair | Outperform |
2022-12-06 | ダウングレード | Jefferies | Buy → Hold |
2022-09-06 | 開始されました | Piper Sandler | Overweight |
2021-04-07 | アップグレード | Maxim Group | Hold → Buy |
2020-12-22 | ダウングレード | Maxim Group | Buy → Hold |
2020-12-04 | ダウングレード | Chardan Capital Markets | Neutral → Sell |
2020-10-22 | 開始されました | RBC Capital Mkts | Sector Perform |
2020-08-14 | 繰り返されました | Maxim Group | Buy |
2020-05-28 | 繰り返されました | H.C. Wainwright | Buy |
2019-01-31 | 再開されました | H.C. Wainwright | Buy |
2018-03-22 | ダウングレード | Credit Suisse | Neutral → Underperform |
2018-02-28 | 繰り返されました | Cantor Fitzgerald | Buy |
2017-08-31 | 開始されました | Oppenheimer | Outperform |
2017-06-08 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Mesoblast Ltd Adr (MESO) 最新ニュース
Mesoblast stock soars to 52-week high, hits $11.1 - Investing.com
Mesoblast files annual report and meeting notice - Investing.com India
Mesoblast stock soars to 52-week high, hits $8.7 - Investing.com
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch - GlobeNewswire Inc.
Mesoblast stock gains momentum ahead of 2025 PDUFA dateJefferies - Investing.com
The Psychology of Mesoblast Ltd ADR Inc. (MESO) Price Performance: Understanding Market Sentiment - The InvestChronicle
Why Argosy Minerals, Flight Centre, Mesoblast, and Telix shares are sinking today - The Motley Fool
Australia stocks higher at close of trade; S&P/ASX 200 up 0.50% - Investing.com
Up 308% in 6 months, why is the Mesoblast share price tumbling today? - The Motley Fool
Australia stocks higher at close of trade; S&P/ASX 200 up 0.73% - Investing.com
Why Clinuvel, Mesoblast, Red Hill, and Resimac shares are sinking today - The Motley Fool
What's going on with the Mesoblast share price today? - The Motley Fool
Australia stocks higher at close of trade; S&P/ASX 200 up 1.19% By Investing.com - Investing.com
Australia shares higher at close of trade; S&P/ASX 200 up 0.34% - Investing.com India
Australia shares higher at close of trade; S&P/ASX 200 up 1.01% - Investing.com India
Mesoblast LtdADR (MESO) Price Target Increased by 5.79% to 1.56 - MSN
There is no doubt that Mesoblast Ltd ADR (MESO) ticks all the boxes. – Sete News - SETE News
Australia stocks higher at close of trade; S&P/ASX 200 up 0.81% - Investing.com
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Australia stocks lower at close of trade; S&P/ASX 200 down 0.09% By Investing.com - Investing.com
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Australia stocks higher at close of trade; S&P/ASX 200 up 0.99% - Investing.com
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
11 Best ASX Stocks To Buy Now - Yahoo Finance
Australia stocks higher at close of trade; S&P/ASX 200 up 0.11% By Investing.com - Investing.com
Australia stocks higher at close of trade; S&P/ASX 200 up 0.39% By Investing.com - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Stock Set to Reverse Split on Friday, January 5th (NASDAQ:MESO) - MarketBeat
Top Penny Stocks for Q3 2023 - Investopedia
Here’s why Mesoblast shares are in a trading halt today - The Motley Fool Australia
Class action proposed against biotech Mesoblast after historic collapse in share price - Business News Australia
The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data - Benzinga
41 Stocks Moving in Friday's Pre-Market SessionAmarin Corp (NASDAQ:AMRN), Artelo Biosciences (NASDAQ:A - Benzinga
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs - Yahoo Finance
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Sh - Benzinga
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rock - Benzinga
The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves I - Benzinga
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEOi - Benzinga
Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse BearishMesoblast (NASDAQ:MESO) - Benzinga
12 Biggest Mid-Day Losers For ThursdayAvalon Holdings (AMEX:AWX) - Benzinga
Exclusive Interview With Pluristem Therapeutics Inc.(NASDAQ:PSTI) President Yaky Yanay - Market Exclusive
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) On Track to Becoming Largest Generics Manufacturer - The Wall Street Transcript
Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology - Streetwise Reports
Mesoblast Ltd Adr (MESO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):